These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 24675038)

  • 1. Feasibility of pegylated interferon and ribavirin in hepatitis C-related cirrhosis with neutropenia or thrombocytopenia.
    Iacobellis A; Cozzolongo R; Minerva N; Valvano MR; Niro GA; Fontana R; Palmieri O; Ippolito A; Andriulli A
    Dig Liver Dis; 2014 Jul; 46(7):621-4. PubMed ID: 24675038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of severe haematological toxicity secondary to pegylated interferon plus ribavirin treatment in HIV-HCV-coinfected patients.
    Mira JA; López-Cortés LF; Merino D; Arizcorreta-Yarza A; Rivero A; Collado A; Ríos-Villegas MJ; González-Serrano M; Torres-Tortoso M; Macías J; Valera-Bestard B; Fernández-Fuertes E; Girón-González JA; Lozano F; Pineda JA;
    Antivir Ther; 2007; 12(8):1225-35. PubMed ID: 18240862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incident severe thrombocytopenia in veterans treated with pegylated interferon plus ribavirin for chronic hepatitis C infection.
    Hermos JA; Quach L; Gagnon DR; Weber HC; Altincatal A; Cho K; Lawler EV; Grotzinger KM
    Pharmacoepidemiol Drug Saf; 2014 May; 23(5):480-8. PubMed ID: 24677630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence and predictors of hematological side effects in chronic HCV Egyptian patients treated with PEGylated interferon and ribavirin.
    Lashin AH; Shaheen YA; Metwally MA; El-Feky HM; Hegab MF; Abbas SM
    Indian J Gastroenterol; 2013 Sep; 32(5):316-23. PubMed ID: 23715642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy.
    Afdhal NH; Dusheiko GM; Giannini EG; Chen PJ; Han KH; Mohsin A; Rodriguez-Torres M; Rugina S; Bakulin I; Lawitz E; Shiffman ML; Tayyab GU; Poordad F; Kamel YM; Brainsky A; Geib J; Vasey SY; Patwardhan R; Campbell FM; Theodore D
    Gastroenterology; 2014 Feb; 146(2):442-52.e1. PubMed ID: 24126097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cirrhosis but not neutropenia is associated with the development of infection in patients with chronic hepatitis C undergoing treatment with pegylated interferon-alpha and ribavirin.
    Striki A; Manolakopoulos S; Deutsch M; Mela M; Kalafateli M; Schini M; Anagnostou O; Triantos C; Andreadis I; Ketikoglou I; Papatheodoridis G; Pectasides D
    J Viral Hepat; 2014; 21(9):624-32. PubMed ID: 24224747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The study of relationship between neutropenia and infection during treatment with peginterferon α and ribavirin for chronic hepatitis C.
    Yu JW; Sun LJ; Zhao YH; Kang P; Yan BZ
    Eur J Gastroenterol Hepatol; 2011 Nov; 23(12):1192-9. PubMed ID: 21971375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin.
    Antonini MG; Babudieri S; Maida I; Baiguera C; Zanini B; Fenu L; Dettori G; Manno D; Mura MS; Carosi G; Puoti M
    Infection; 2008 Jun; 36(3):250-5. PubMed ID: 18458815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence and severity of infections according to the development of neutropenia during combined therapy with pegylated interferon-alpha2a plus ribavirin in chronic hepatitis C infection.
    Juarez-Navarro A; Vera-de-León L; Navarro JM; Chirino-Sprung R; Díaz-Hernandez M; Casillas-Davila L; Dehesa-Violante M
    Methods Find Exp Clin Pharmacol; 2005 Jun; 27(5):317-22. PubMed ID: 16082419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of infections during interferon-based treatment in patients with chronic hepatitis C virus infection and advanced hepatic fibrosis.
    Maan R; van der Meer AJ; Hansen BE; Feld JJ; Wedemeyer H; Dufour JF; Lammert F; Manns MP; Zeuzem S; Janssen HL; de Knegt RJ; Veldt BJ
    J Gastroenterol Hepatol; 2015 Jun; 30(6):1057-64. PubMed ID: 25682797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytopenias during treatment of HIV-HCV-coinfection with pegylated interferon and ribavirin: safety analysis of the OPERA study.
    Pontali E; Angeli E; Cattelan AM; Maida I; Nasta P; Verucchi G; Caputo A; Iannacone C; Puoti M
    Antivir Ther; 2015; 20(1):39-48. PubMed ID: 24831457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombocytopenia and the risk of bleeding during treatment with peginterferon alfa and ribavirin for chronic hepatitis C.
    Roomer R; Hansen BE; Janssen HL; de Knegt RJ
    J Hepatol; 2010 Sep; 53(3):455-9. PubMed ID: 20561709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe thrombocytopenia in a patient with inosine triphosphatase (ITPA)-CC genotype caused by pegylated interferon (IFN)-α-2a with ribavirin therapy: a case report.
    Jiang W; Hidaka H; Nakazawa T; Kitagawa H; Koizumi W
    BMC Res Notes; 2014 Mar; 7():141. PubMed ID: 24621321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modifications of haematological series in patients co-infected with human immunodeficiency virus and hepatitis C virus during treatment with interferon and ribavirin: differences between pegylated and standard interferon.
    Arizcorreta A; Brun F; Fernández-Gutiérrez C; García Juárez R; Guerrero F; Pérez-Guzmán E; Girón-González JA
    Clin Microbiol Infect; 2004 Dec; 10(12):1067-74. PubMed ID: 15606633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Side-effects of pegylated interferon plus ribavirin therapy with or without protease inhibitor direct acting antiviral agents during treatment of chronic hepatitis C virus infection].
    Hunyady B; Kovács B; Battyáni Z
    Orv Hetil; 2011 Dec; 152(50):1997-2009. PubMed ID: 22112373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical efficacy and safety of the combination therapy of peginterferon alpha and ribavirin in cirrhotic patients with HCV infection].
    Cheong HR; Woo HY; Heo J; Yoon KT; Kim DU; Kim GH; Kang DH; Song GA; Cho M
    Korean J Hepatol; 2010 Mar; 16(1):38-48. PubMed ID: 20375641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors for infection during treatment with peginterferon alfa and ribavirin for chronic hepatitis C.
    Roomer R; Hansen BE; Janssen HL; de Knegt RJ
    Hepatology; 2010 Oct; 52(4):1225-31. PubMed ID: 20830784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic effect of response to interferon therapy after laparoscopic splenectomy among patients with marked thrombocytopenia and hepatitis C virus-related cirrhosis.
    Tamai H; Mori Y; Shingaki N; Shimizu R; Nuta J; Moribata K; Maeda Y; Muraki Y; Deguchi H; Inoue I; Maekita T; Iguchi M; Kato J; Takifuji K; Yamaue H; Ichinose M
    Hepatol Int; 2015 Jan; 9(1):67-75. PubMed ID: 25788381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of thrombocytopenia on treatment tolerability and outcome in patients with chronic HCV infection and advanced hepatic fibrosis.
    Maan R; van der Meer AJ; Hansen BE; Feld JJ; Wedemeyer H; Dufour JF; Zangneh HF; Lammert F; Manns MP; Zeuzem S; Janssen HL; de Knegt RJ; Veldt BJ
    J Hepatol; 2014 Sep; 61(3):482-91. PubMed ID: 24780302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review article: optimizing SVR and management of the haematological side effects of peginterferon/ribavirin antiviral therapy for HCV - the role of epoetin, G-CSF and novel agents.
    Mac Nicholas R; Norris S
    Aliment Pharmacol Ther; 2010 May; 31(9):929-37. PubMed ID: 20175767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.